Study findings suggest using the drug PF-06409577 to restore CDX2 in colon cancers could cut risk of recurrence and death by up to 50%.

There are currently no available treatment options for more than 90% of the approximately 7,000 rare diseases identified to ...

By combining proteasome inhibitors with Lys05, a drug that impairs autophagy, the team was able to shut down AML’s detour. In ...

Scientists have found a new way to stop cancer growth without damaging healthy cells. Researchers from the Francis Crick Institute and Vividion Therapeutics discovered a compound that blocks the ...

A new 3D human brain tissue platform developed by MIT researchers is the first to integrate all major brain cell types, ...

Kite has paid $120 million upfront to Pregene to gain certain license rights and to collaborate on developing in vivo cell therapies with the Shenzhen, China-based firm. Pregene is entitled to receive ...

The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic fle ...

Controlling the state of a cell in a desired direction is one of the central challenges in life sciences, including drug development, cancer treatment, and regenerative medicine.

Sana Biotechnology, Inc. is working on a gene therapy to cure Type 1 diabetes. Click here to find out why SANA stock is a ...

The 2022 Option Agreement between Astellas and Taysha has expired. Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value w ...

Long-term follow-up shows 95% success rate, no serious complications in largest ADA-SCID gene therapy study to date ...